uric acid has been researched along with Angiitis in 9 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Excerpt | Relevance | Reference |
---|---|---|
"High serum uric acid (SUA) levels are present in patients with metabolic syndrome (MetS), when the latter is associated with endothelial dysfunction, inflammation, and hypertension." | 3.81 | Association of serum uric acid levels to inflammation biomarkers and endothelial dysfunction in obese prepubertal children. ( Bermudo, F; Cañete, MD; Cañete, R; Martos, R; Valle, M; Valle, R; van Donkelaar, EL, 2015) |
" The relationship between calcium oxalate (COX) crystals - implicated in the vasculitis of primary oxalosis - and immunologically mediated endothelial injury was also explored." | 3.66 | Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury. ( Boogaerts, MA; Hammerschmidt, DE; Jacob, HS; Roelant, C; Verwilghen, RL, 1983) |
"Uric acid (UA) has been found to stimulate macrophage migration inhibitory factor (MIF) up-regulation in renal tubules from rats subjected to UA-induced nephropathy." | 1.51 | Blockage of macrophage migration inhibitory factor (MIF) suppressed uric acid-induced vascular inflammation, smooth muscle cell de-differentiation, and remodeling. ( Fu, X; Li, G; Liu, Q; Lou, Y; Mei, J; Niu, N; Qu, P; Sui, Z; Sun, J; Xu, M, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (22.22) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 2 (22.22) | 2.80 |
Authors | Studies |
---|---|
Drosos, GC | 1 |
Vedder, D | 1 |
Houben, E | 1 |
Boekel, L | 1 |
Atzeni, F | 1 |
Badreh, S | 1 |
Boumpas, DT | 1 |
Brodin, N | 1 |
Bruce, IN | 1 |
González-Gay, MÁ | 1 |
Jacobsen, S | 1 |
Kerekes, G | 1 |
Marchiori, F | 1 |
Mukhtyar, C | 1 |
Ramos-Casals, M | 1 |
Sattar, N | 1 |
Schreiber, K | 1 |
Sciascia, S | 1 |
Svenungsson, E | 1 |
Szekanecz, Z | 1 |
Tausche, AK | 1 |
Tyndall, A | 1 |
van Halm, V | 1 |
Voskuyl, A | 1 |
Macfarlane, GJ | 1 |
Ward, MM | 1 |
Nurmohamed, MT | 1 |
Tektonidou, MG | 1 |
Sessa, C | 1 |
Granata, A | 1 |
Gaudio, A | 1 |
Xourafa, A | 1 |
Malatino, L | 1 |
Lentini, P | 1 |
Fatuzzo, P | 1 |
Rapisarda, F | 1 |
Castellino, P | 1 |
Zanoli, L | 1 |
Fu, X | 1 |
Niu, N | 1 |
Li, G | 1 |
Xu, M | 1 |
Lou, Y | 1 |
Mei, J | 1 |
Liu, Q | 1 |
Sui, Z | 1 |
Sun, J | 1 |
Qu, P | 1 |
Valle, M | 1 |
Martos, R | 1 |
Cañete, MD | 1 |
Valle, R | 1 |
van Donkelaar, EL | 1 |
Bermudo, F | 1 |
Cañete, R | 1 |
Rajtar, R | 1 |
Kloch, M | 1 |
Bober, M | 1 |
Kolasińska-Kloch, W | 1 |
Boogaerts, MA | 1 |
Hammerschmidt, DE | 1 |
Roelant, C | 1 |
Verwilghen, RL | 1 |
Jacob, HS | 1 |
Zhioua, R | 1 |
Sebaï, L | 1 |
Kriaa, L | 1 |
el Euch, M | 1 |
Mabrouk, S | 1 |
Ouertani, A | 1 |
Meneshian, A | 1 |
Bulkley, GB | 1 |
Coutellier, P | 1 |
Delgrange, B | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Paediatric Obesity and Cardiovascular Dysfunction: Searching for Early Markers of Damage[NCT03169257] | 100 participants (Actual) | Interventional | 2015-01-15 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
3 reviews available for uric acid and Angiitis
Article | Year |
---|---|
[Vascular dysfunction in Cardiorenal Syndrome type 4].
Topics: Aorta; Arginine; Autonomic Nervous System Diseases; Bone Diseases, Metabolic; Cardio-Renal Syndrome; | 2020 |
[The current opinion on inflammatory, biochemistry and hemostatic markers and factors in atherosclerosis. Part II].
Topics: Animals; Atherosclerosis; Biomarkers; Causality; Clinical Trials as Topic; Comorbidity; Fibrin Fibri | 2006 |
The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction.
Topics: Animals; Endothelium, Vascular; Humans; Reperfusion Injury; Signal Transduction; Uric Acid; Vasculit | 2002 |
6 other studies available for uric acid and Angiitis
Article | Year |
---|---|
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Cardiovascular Diseases; Gout; Heart Disease Risk Factors; Humans; Lupus | 2022 |
Blockage of macrophage migration inhibitory factor (MIF) suppressed uric acid-induced vascular inflammation, smooth muscle cell de-differentiation, and remodeling.
Topics: Animals; Cell Dedifferentiation; Cells, Cultured; Disease Models, Animal; Gene Knockdown Techniques; | 2019 |
Association of serum uric acid levels to inflammation biomarkers and endothelial dysfunction in obese prepubertal children.
Topics: Biomarkers; Body Mass Index; C-Reactive Protein; Child; Cross-Sectional Studies; Endothelium, Vascul | 2015 |
Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury.
Topics: Blood Physiological Phenomena; Blood Platelets; Calcium Oxalate; Cell Adhesion; Cell Aggregation; Co | 1983 |
[Risk factors and etiology of retinal vein occlusion].
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Behcet Syndrome; Coronary Disease; Diabetes Complication | 1995 |
[Fatal toxic epidermolysis following administration of allopurinol].
Topics: Aged; Allopurinol; Epidermolysis Bullosa; Gastrointestinal Hemorrhage; Humans; Kidney Failure, Chron | 1989 |